J&J pays $2.2 billion upfront for an eye drug whose Phase 3 trial Blackstone will fund

Johnson & Johnson agreed to buy Ollin Biosciences on November 16, with up to about $1.125 billion more in milestones and $750 million of trial funding from Blackstone.

Add FinanceInTime as a preferred source on Google
Illustration of an empty eye-clinic examination room with a slit-lamp microscope and a chair in morning light
Illustration. Not a photo of a Johnson & Johnson or Ollin facility.Illustration: FinanceInTime

Johnson & Johnson (NYSE: JNJ) agreed on November 16 to acquire Ollin Biosciences, a clinical-stage developer of eye-disease therapies, for $2.2 billion upfront plus milestone payments of up to about $1.125 billion, the company said.

The price is split between closing and later milestones

J&J said it entered into a definitive agreement to buy Ollin for $2.2 billion upfront, "with the potential for additional regulatory and commercial milestone payments." The milestones could reach approximately $1.125 billion, which would bring the total to about $3.3 billion (computed: $2.2 billion plus $1.125 billion).

The company said it expects the transaction to close before the end of 2026, subject to applicable regulatory approvals and customary closing conditions.

A second company pays for the late-stage trial

Alongside the acquisition, J&J will sign a development funding agreement with Blackstone Life Sciences. Blackstone will pay J&J a total of $750 million over multiple years to fully fund the Phase 3 development of the drug, and in return will be eligible for certain regulatory and sales milestone payments as well as single-digit royalties, according to J&J. The agreement is contingent on the acquisition closing.

J&J said the accounting treatment of the arrangement will be communicated on or before the close of the transaction.

One antibody aimed at two pathways in the eye

The asset is OLN324, an investigational bispecific antibody designed to target two pathways in retinal disease: vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2). It is being developed for wet age-related macular degeneration and diabetic macular edema, conditions that together affect more than 40 million people worldwide, the company said.

"OLN324 selectively targets two important drivers of retinal disease and has the potential to achieve stronger and more sustained disease control," said Kip Connor, J&J's Vice President and Ophthalmology Disease Area Stronghold Leader. The drug is in Phase 3, so it has not yet been approved for any use.

The deal follows a quarter of other acquisitions and collaborations

J&J reported third-quarter 2026 sales of $25.4 billion, up 5.9% from a year earlier, in a results release filed with the SEC on October 13. Its third-quarter earnings per share of $0.09 reflected a one-time special charge for the proposed talc litigation resolution, the acquisition of Firefly Bio and a strategic collaboration with Sail Biomedicines, the company said.

Sales of Stelara, an immunology drug, reduced growth by approximately 690 basis points in the quarter. In the same release, Chairman and CEO Joaquin Duato said the company's strategic investments in high-growth areas give it "clearer line of sight to double-digit growth by the end of the decade."

J&J estimated free cash flow of about $15.1 billion for the first nine months of 2026. The $2.2 billion upfront payment equals about 14.6% of that figure (computed).

Paying upfront for a trial that is funded elsewhere

We think the structure matters more than the headline price. Blackstone's $750 million covers the Phase 3 costs, so J&J pays $2.2 billion upfront for a drug whose late-stage trial is financed by someone else, and gives up single-digit royalties and some milestones in return. That fits our reading of capital allocation: J&J is buying pipeline while sharing the trial risk with an outside investor, and the Stelara drag on growth is the backdrop against which it does so.

The opportunity is a product in a large eye-disease market if the Phase 3 results hold. The threat is that a late-stage drug can still fail, and the milestones and royalties would then count against a smaller prize. We expect the next test to be the accounting disclosure due by closing; our view would change if it shows a larger net cost than the upfront price suggests.

The view in this final section is FinanceInTime's editorial opinion, for information only. It is not investment, tax, legal or other advice, and it does not take your circumstances into account. Forecasts are uncertain and past results do not guarantee future ones.

Sources

  1. Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology — Johnson & JohnsonPrimary source
  2. Johnson & Johnson reports Q3 2026 results, raises 2026 guidance (Exhibit 99.1) — Johnson & Johnson / SECPrimary source
Add FinanceInTime as a preferred source on Google

More in Business

View All Business

Get Finance News in Your Inbox

Daily headlines, market insights and analysis from our editors.